Autoantibodies neutralizing type I IFNs underlie severe tick-borne encephalitis in ∼10% of patients

Adrian Gervais,Astrid Marchal,Andrea Fortova,Michaela Berankova,Lenka Krbkova,Martina Pychova,Jiri Salat,Shuxiang Zhao,Nacim Kerrouche,Tom Le Voyer,Karin Stiasny,Simon Raffl,Anne Schieber Pachart,Samira Fafi-Kremer,Simon Gravier,Davide F Robbiani,Laurent Abel,Margaret R MacDonald,Charles M Rice,Gaia Weissmann,Tarek Kamal Eldin,Eva Robatscher,Elke Maria Erne,Elisabetta Pagani,Alessandro Borghesi,Anne Puel,Paul Bastard,Aurélie Velay,Martin Martinot,Yves Hansmann,Judith H Aberle,Daniel Ruzek,Aurélie Cobat,Shen-Ying Zhang,Jean-Laurent Casanova

DOI: https://doi.org/10.1084/jem.20240637

2024-10-07

Abstract:Tick-borne encephalitis (TBE) virus (TBEV) is transmitted to humans via tick bites. Infection is benign in >90% of the cases but can cause mild (<5%), moderate (<4%), or severe (<1%) encephalitis. We show here that ∼10% of patients hospitalized for severe TBE in cohorts from Austria, Czech Republic, and France carry auto-Abs neutralizing IFN-α2, -β, and/or -ω at the onset of disease, contrasting with only ∼1% of patients with moderate and mild TBE. These auto-Abs were found in two of eight patients who died and none of 13 with silent infection. The odds ratios (OR) for severe TBE in individuals with these auto-Abs relative to those without them in the general population were 4.9 (95% CI: 1.5-15.9, P < 0.0001) for the neutralization of only 100 pg/ml IFN-α2 and/or -ω, and 20.8 (95% CI: 4.5-97.4, P < 0.0001) for the neutralization of 10 ng/ml IFN-α2 and -ω. Auto-Abs neutralizing type I IFNs accounted for ∼10% of severe TBE cases in these three European cohorts.